Use of pagoclone for the treatment of social anxiety disorder

US7553847B2 · kind B2 · utility

Assignee

• Indevus Pharmaceuticals, Inc. · US

Inventors

• Cathryn Clary · New York, US
• Jeroen Van Beek · Hoboken, BE
• Perry S. Eisman · Southampton, US
• Sean Donevan · Dexter, US
• Atul Pande · East Lyme, US
• Richard Kavoussi · Ann Arbor, US
• Lyou-Fu Ma · Ann Arbor, US

Key dates

• Filing date: Feb 13, 2006
• Grant date: Jun 30, 2009
• Expiry date: Feb 13, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods for treating social anxiety disorder, comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone or pharmaceutically acceptable salt, or optical isomer therof, and optionally comprising administering another compound for the treatment of social anxiety disorder that is a GABA agonist.